scholarly journals Declining Intensive Care Unit Mortality of COVID-19: A Multi-Center Study

2021 ◽  
Vol 13 (3) ◽  
pp. 184-190
Author(s):  
Sohaib Roomi ◽  
Syed Omar Shah ◽  
Waqas Ullah ◽  
Shan Ul Abedin ◽  
Karyn Butler ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Intensive Care Unit Mortality ◽  
Multi Center Study ◽  
Center Study

Nighttime Cross-Coverage Is Associated with Decreased Intensive Care Unit Mortality. A Single-Center Study

2014 ◽  
Vol 189 (11) ◽  
pp. 1395-1401 ◽  
Author(s):  
Andre Carlos Kajdacsy-Balla Amaral ◽  
Bernardo S. Barros ◽  
Camilla C. P. P. Barros ◽  
Cameron Innes ◽  
Ruxandra Pinto ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Intensive Care Unit Mortality ◽  
Single Center ◽  
Single Center Study ◽  
Center Study

scholarly journals Infections in hematopoietic stem cell transplant patients admitted to Hematology intensive care unit: a single-center study

Hematology ◽  
2021 ◽  
Vol 26 (1) ◽  
pp. 328-339
Author(s):  
Tuğba Barlas ◽  
Kamil İnci ◽  
Gulbin Aygencel ◽  
Melda Türkoğlu ◽  
Özlem Güzel Tunçcan ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Hematopoietic Stem Cell Transplant ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Single Center ◽  
Hematopoietic Stem ◽  
Transplant Patients ◽  
Single Center Study ◽  
Center Study

scholarly journals Effect of Aprotinin and Avifavir® Combination Therapy for Moderate COVID-19 Patients

Viruses ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1253
Author(s):  
Andrey A. Ivashchenko ◽  
Valeria N. Azarova ◽  
Alina N. Egorova ◽  
Ruben N. Karapetian ◽  
Dmitry V. Kravchenko ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Body Temperature ◽  
Combination Therapy ◽  
Serine Proteases ◽  
Clinical Status ◽  
Single Center ◽  
Single Center Study ◽  
D Dimer ◽  
Center Study

COVID-19 is a contagious multisystem inflammatory disease caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We studied the efficacy of Aprotinin (nonspecific serine proteases inhibitor) in combination with Avifavir® or Hydroxychloroquine (HCQ) drugs, which are recommended by the Russian Ministry of Health for the treatment therapy of moderate COVID-19 patients. This prospective single-center study included participants with moderate COVID-19-related pneumonia, laboratory-confirmed SARS-CoV-2, and admitted to the hospitals. Patients received combinations of intravenous (IV) Aprotinin (1,000,000 KIU daily, 3 days) and HCQ (cohort 1), inhalation (inh) treatment with Aprotinin (625 KIU four times per day, 5 days) and HCQ (cohort 2) or IV Aprotinin (1,000,000 KIU daily for 5 days) and Avifavir (cohort 3). In cohorts 1–3, the combination therapy showed 100% efficacy in preventing the transfer of patients (n = 30) to the intensive care unit (ICU). The effect of the combination therapy in cohort 3 was the most prominent, and the median time to SARS-CoV-2 elimination was 3.5 days (IQR 3.0–4.0), normalization of the CRP concentration was 3.5 days (IQR 3–5), of the D-dimer concentration was 5 days (IQR 4 to 5); body temperature was 1 day (IQR 1–3), improvement in clinical status or discharge from the hospital was 5 days (IQR 5–5), and improvement in lung lesions of patients on 14 day was 100%.

An examination of cardiovascular intensive care unit mortality based on admission day and time

Heart & Lung ◽  
2021 ◽  
Vol 50 (5) ◽  
pp. 579-586
Author(s):  
Matthew C. Langston ◽  
Keshab Subedi ◽  
Carly Fabrizio ◽  
Neil J. Wimmer ◽  
Usman I. Choudhry ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Intensive Care Unit Mortality ◽  
Cardiovascular Intensive Care
Sign in / Sign up

Export Citation Format

Share Document